Emcure Pharma IPO Financials
The Emcure Pharma IPO provide an overview of the company's performance over the previous financial periods. Investors can evaluate key financial metrics such as assets, revenue, profit after tax (PAT), net worth, reserves & surplus, and total borrowings to assess the company's financial strength, profitability, and long-term growth potential before investing in the IPO.
As of 31 Mar 24, Emcure Pharmaceuticals Limited reported assets of ₹7,806.16 crore, revenue of ₹6,715.24 crore, and a profit after tax (PAT) of ₹527.58 crore. The company had a net worth of ₹2,952.28 crore and reserves & surplus of ₹2,722.4 crore, and total borrowings are 2,091.94 crore.
Revenue decreased by 10.18% in 31 Mar 23 and decreased by 1.87% in 31 Mar 22, while Profit After Tax (PAT) grew by 6.50% in 31 Mar 23 and grew by 25.04% in 31 Mar 22, respectively.
*Info is indicative. Not an Investment Advice. Grey market trading is unregulated.
Emcure Pharmaceuticals Limited Financials (₹ in Crores)
| Particular | 31 Mar 24 | 31 Mar 23 | 31 Mar 22 |
|---|---|---|---|
| Assets | 7806.16 | 6672.53 | 6063.47 |
| Revenue | 6715.24 | 6031.72 | 5918.86 |
| Profit After Tax | 527.58 | 561.85 | 702.56 |
| Net Worth | 2952.28 | 2501.13 | 1987.55 |
| Reserve & Surplus | 2722.4 | 2293.77 | 1791.03 |
| Total Borrowings | 2091.94 | 2202.42 | 2102.19 |
EPS Pre
29.17%
EPS Post
27.95%
P/E Pre
34.55
P/E (Post Issue)
36.07x
Company Financial Information
Disclaimer: This data is for informational purposes only and does not constitute investment advice. Figures shown are illustrative sample data.
Frequently Asked Questions
Everything you need to know before applying to an IPO.
What is the Revenue of Emcure Pharmaceuticals Limited?
Emcure Pharmaceuticals Limited reported revenue of ₹6715.24 crore as of 31 Mar 24. Revenue figures from the Emcure Pharma IPO provide insights into sales growth, market demand, and business scalability.
What is the Profit After Tax (PAT) of Emcure Pharmaceuticals Limited?
Emcure Pharmaceuticals Limited reported a Profit After Tax (PAT) of ₹527.58 crore as of 31 Mar 24. PAT represents the company's net profit after deducting all operating expenses, interest, taxes, and other applicable charges, making it a key indicator of overall profitability.
What is the PE Ratio of Emcure Pharmaceuticals Limited?
Emcure Pharmaceuticals Limited has a Price-to-Earnings (P/E) ratio of 34.55x based on the IPO issue price. The P/E ratio compares the company's share price with its earnings per share (EPS) and is a commonly used valuation metric to assess whether a stock is fairly valued relative to its earnings and industry peers.